[Regulative effect of genistein on xenografted tumor of ovarian carcinoma cell on nude mice].
OBJECTIVE
To investigate the regulative effect of genistein on the apoptosis of the xenografted tumors of human ovarian carcinoma HO-8910PM cell on the nude mice.


METHODS
Human ovarian carcinoma HO-8910PM were cultured in vitro. The models of xenografted tumor were established by the transplantation of human ovarian carcinoma HO-8910PM on nude mice. The nude mice were randomly divided into four groups of three treatment groups (in which genistein were administered ip at 5, 25 and 50 mg x kg(-1) x d(-1), respectively, for 4 weeks) and one control group, the cell cycle and apoptosis of the xenografted tumors were measured by flow cytometry, the expression of bcl-2, Fas and FasL gene of xenografted tumors were determined by the immunohistochemistry and the morphology of tumor cells was observed by electron microscope.


RESULTS
The tumor weights of 50 mg x xkg(-1) genistein group were more lighter (P < 0.05) compared to those of control group. The tumor cells in Go-G1 phase were increased, at saml time the cells in S-phase were decreased (P < 0.01) after the treatment of 50 mg x kg(-1) genistein. In addition the apoptosis rate of the cell treated with 50 mg x kg(-1) genistein group was (15.14 +/- 2.27)%, which was significantly higher than that in the control group (3.12 +/- 1.12)% (P < 0.01). The expression of bcl-2 of the xenografted tumors was decreased and the expression of Fas was increased in 50 mg x kg(-1) genistein group, both showing a significant difference from those in control group (P < 0.05). The apoptosis of the tumor cells were found more under electron microscopy in 50 mg x kg(-1) genistein group than those in control group.


CONCLUSIONS
Genistein could significantly inhibite the proliferation and induce the apoptosis of the HO-8910PM cell of xenografted tumors by regulating the cell cycle and apoptoic gene in the nude mice.
Wang
Xin
X
Xi Jing Hospital, Fourth Military Medical University of Chinese PLA, Xi'an 710032, China.
Xin
Xiao-yan
XY
Huang
Yan-hong
YH
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D053222:Fas Ligand Protein / Q000378:metabolism; D005260:Female; D019833:Genistein / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D011897:Random Allocation; D019014:fas Receptor / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D053222:Fas Ligand Protein; D019253:Proto-Oncogene Proteins c-bcl-2; D019014:fas Receptor; D019833:Genistein